Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OK3O
|
|||
| Former ID |
DCL001170
|
|||
| Drug Name |
Cenderitide
|
|||
| Indication | Heart disease [ICD-11: BA41-BA42; ICD-9: 390-429] | Phase 2 | [1] | |
| Heart failure [ICD-11: BD10-BD13; ICD-10: I50, I50.9; ICD-9: 428] | Phase 1 | [2] | ||
| Company |
Nile Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Atrial natriuretic peptide receptor A (NPR1) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressurein a proof-of-concept study in patients with chronic heart failure. BMC Pharmacol. 2011; 11(Suppl 1): P18. | |||
| REF 2 | 2011 Pipeline of Nile Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.